ADVFN Logo
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

SNGX Soligenix Inc

0.60
-0.0071 (-1.17%)
Mar 28 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 137,612
Bid Price 0.6001
Ask Price 0.65
News -
Day High 0.61

Low
0.38

52 Week Range

High
4.20

Day Low 0.5924
Company Name Stock Ticker Symbol Market Type
Soligenix Inc SNGX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.0071 -1.17% 0.60 20:00:00
Open Price Low Price High Price Close Price Prev Close
0.593 0.5924 0.61 0.60 0.6071
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
315 137,612 $ 0.6000464 $ 82,574 - 0.38 - 4.20
Last Trade Time Type Quantity Stock Price Currency
18:50:56 8 $ 0.6001 USD

Soligenix Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
6.23M 10.38M - 949k -13.8M -1.33 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Soligenix News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No SNGX Message Board. Create One! See More Posts on SNGX Message Board See More Message Board Posts

Historical SNGX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.64620.660.570.60913961,649-0.0462-7.15%
1 Month0.730.8250.570.7068147106,455-0.13-17.81%
3 Months0.94990.980.55550.8297872309,442-0.3499-36.84%
6 Months0.53572.000.380.89756791,557,1280.064312.00%
1 Year1.884.200.381.091,043,268-1.28-68.09%
3 Years23.2524.300.388.01682,203-22.65-97.42%
5 Years13.6555.200.3817.68821,549-13.05-95.60%

Soligenix Description

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).

Your Recent History

Delayed Upgrade Clock